ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C - quarterly
|
|
Opfan17
|
203 |
93K |
13 |
29/04/20 |
29/04/20 |
ASX - By Stock
|
203
|
93K
|
13
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
8 |
28/04/20 |
28/04/20 |
ASX - By Stock
|
23K
|
13M
|
8
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
20 |
27/04/20 |
27/04/20 |
ASX - By Stock
|
23K
|
13M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
FOMO Time
|
|
Opfan17
|
28 |
11K |
3 |
27/04/20 |
27/04/20 |
ASX - By Stock
|
28
|
11K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
FOMO Time
|
|
Opfan17
|
28 |
11K |
4 |
27/04/20 |
27/04/20 |
ASX - By Stock
|
28
|
11K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Tank time- TIMMMBBEERRR
|
|
Opfan17
|
304 |
130K |
2 |
27/04/20 |
27/04/20 |
ASX - By Stock
|
304
|
130K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
|
|
Opfan17
|
847 |
332K |
6 |
25/04/20 |
25/04/20 |
ASX - By Stock
|
847
|
332K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
|
|
Opfan17
|
847 |
332K |
3 |
25/04/20 |
25/04/20 |
ASX - By Stock
|
847
|
332K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
|
|
Opfan17
|
847 |
332K |
35 |
25/04/20 |
25/04/20 |
ASX - By Stock
|
847
|
332K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
MESO action tonight
|
|
Opfan17
|
3.1K |
1.4M |
31 |
25/04/20 |
25/04/20 |
ASX - By Stock
|
3.1K
|
1.4M
|
31
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
|
|
Opfan17
|
847 |
332K |
14 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
847
|
332K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
|
|
Opfan17
|
847 |
332K |
19 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
847
|
332K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
8 |
23/04/20 |
23/04/20 |
ASX - By Stock
|
17K
|
6.6M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
4 |
19/04/20 |
19/04/20 |
ASX - By Stock
|
17K
|
6.6M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
24 |
15/04/20 |
15/04/20 |
ASX - By Stock
|
23K
|
13M
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Ann: US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial
|
|
Opfan17
|
276 |
139K |
8 |
12/04/20 |
12/04/20 |
ASX - By Stock
|
276
|
139K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Opfan17
|
17K |
6.6M |
29 |
11/04/20 |
11/04/20 |
ASX - By Stock
|
17K
|
6.6M
|
29
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
11 |
07/04/20 |
07/04/20 |
ASX - By Stock
|
23K
|
13M
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients
|
|
Opfan17
|
311 |
164K |
30 |
06/04/20 |
06/04/20 |
ASX - By Stock
|
311
|
164K
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Covid19 watch.
|
|
Opfan17
|
65 |
24K |
3 |
06/04/20 |
06/04/20 |
ASX - By Stock
|
65
|
24K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Athersys vs. Mesoblast
|
|
Opfan17
|
46 |
20K |
12 |
04/04/20 |
04/04/20 |
ASX - By Stock
|
46
|
20K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Treatment of inflammatory diseases
|
|
Opfan17
|
6 |
3.6K |
6 |
03/04/20 |
03/04/20 |
ASX - By Stock
|
6
|
3.6K
|
6
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
6 |
03/04/20 |
03/04/20 |
ASX - By Stock
|
23K
|
13M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Patents
|
|
Opfan17
|
24 |
10K |
18 |
02/04/20 |
02/04/20 |
ASX - By Stock
|
24
|
10K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts BLA for RYONCIL and Agrees to Priority Review
|
|
Opfan17
|
131 |
54K |
16 |
01/04/20 |
01/04/20 |
ASX - By Stock
|
131
|
54K
|
16
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
Opfan17
|
165 |
66K |
3 |
01/04/20 |
01/04/20 |
ASX - By Stock
|
165
|
66K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting
|
|
Opfan17
|
84 |
34K |
7 |
31/03/20 |
31/03/20 |
ASX - By Stock
|
84
|
34K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting
|
|
Opfan17
|
84 |
34K |
7 |
30/03/20 |
30/03/20 |
ASX - By Stock
|
84
|
34K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
New Coronavirus cases falling in Australia
|
|
Opfan17
|
10 |
3.5K |
5 |
30/03/20 |
30/03/20 |
ASX - By Stock
|
10
|
3.5K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
trial time
|
|
Opfan17
|
35 |
15K |
57 |
28/03/20 |
28/03/20 |
ASX - By Stock
|
35
|
15K
|
57
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
4 |
27/03/20 |
27/03/20 |
ASX - By Stock
|
23K
|
13M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
5 |
27/03/20 |
27/03/20 |
ASX - By Stock
|
23K
|
13M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Here's the latest (*******)
|
|
Opfan17
|
69 |
29K |
6 |
27/03/20 |
27/03/20 |
ASX - By Stock
|
69
|
29K
|
6
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
6 |
27/03/20 |
27/03/20 |
ASX - By Stock
|
23K
|
13M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
TWS Transcript - 23rd March 2020
|
|
Opfan17
|
8 |
4.9K |
21 |
25/03/20 |
25/03/20 |
ASX - By Stock
|
8
|
4.9K
|
21
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
18 |
23/03/20 |
23/03/20 |
ASX - By Stock
|
23K
|
13M
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
|
|
Opfan17
|
443 |
197K |
10 |
18/03/20 |
18/03/20 |
ASX - By Stock
|
443
|
197K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
|
|
Opfan17
|
443 |
197K |
22 |
15/03/20 |
15/03/20 |
ASX - By Stock
|
443
|
197K
|
22
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
19 |
12/03/20 |
12/03/20 |
ASX - By Stock
|
23K
|
13M
|
19
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
14 |
12/03/20 |
12/03/20 |
ASX - By Stock
|
23K
|
13M
|
14
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
12 |
12/03/20 |
12/03/20 |
ASX - By Stock
|
23K
|
13M
|
12
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
0 |
11/03/20 |
11/03/20 |
ASX - By Stock
|
23K
|
13M
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
1 |
11/03/20 |
11/03/20 |
ASX - By Stock
|
23K
|
13M
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
5 |
11/03/20 |
11/03/20 |
ASX - By Stock
|
23K
|
13M
|
5
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Opfan17
|
23K |
13M |
11 |
11/03/20 |
11/03/20 |
ASX - By Stock
|
23K
|
13M
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Emergency Use Authorization (EUA)
|
|
Opfan17
|
33 |
14K |
14 |
11/03/20 |
11/03/20 |
ASX - By Stock
|
33
|
14K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
|
|
Opfan17
|
443 |
197K |
22 |
11/03/20 |
11/03/20 |
ASX - By Stock
|
443
|
197K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
|
|
Opfan17
|
443 |
197K |
18 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
443
|
197K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
|
|
Opfan17
|
443 |
197K |
6 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
443
|
197K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cantor Update - MSC's and COVID-19
|
|
Opfan17
|
104 |
48K |
24 |
09/03/20 |
09/03/20 |
ASX - By Stock
|
104
|
48K
|
24
|
|